Signal. Rev. 31, 20–29 (2017). Garrity, D., Call, M. E., Feng, J. Fujisaki, H., Kakuda, H., Imai, C., Mullighan, C. G. & Campana, D. Replicative potential of human natural killer cells. Muller, N. et al. Sci. N.S. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. This article reports that PDGF-DD, produced by tumour cells, is a ligand for the NKp44 activating receptor and stimulates NK cell cytokine and chemokine secretion. Bournazos, S., Wang, T. T., Dahan, R., Maamary, J. Med. 67, 483–494 (2018). Cancer Res. These modifications promise to significantly increase their clinical activity. Eur. Adv Exp Med Biol. None of the authors has non-financial competing interests. Sci. A.J. Szmania, S. et al. (2021), Nature Reviews Drug Discovery Lymphokine-activated killer cell phenomenon. Proc. Immunol. Fehniger, T. A. et al. Rev. Chem. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. The broad cytotoxicity and rapid killing make NK cells ideal for the use in cancer immunotherapy. Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity. Oncoimmunology 4, e1042202 (2015). Groh, V., Wu, J., Yee, C. & Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Shimasaki, N., Jain, A. Blood 127, 3321–3330 (2016). Biol. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. This article describes how expression of mbIL-15 in human NK cells sustains their growth and increases antitumour activity. Nikzad, R. et al. James, A. M. et al. J. Clin. and JavaScript. 140, 853–866 (2013). & Jameson, S. C. In vivo survival and homeostatic proliferation of natural killer cells. 29, 104–113 (2001). Sliz, A. et al. Arch, R. H. & Thompson, C. B. Schlums, H. et al. Rev. IL15 Trispecific killer engagers (TriKE) make natural killer cells specific to CD33+targets while also inducing persistence, in vivo expansion, and enhanced function. Med. A chronic myelogenous leukaemia cell line that expresses the BCR–ABL1 fusion gene, which lacks major histocompatibility complex/human leukocyte antigen surface expression and is commonly used as a target in natural killer (NK) cell cytotoxicity assays. Proc. D.C. has received patent royalties from Juno Therapeutics (a Celgene company), Unum Therapeutics, Nkarta Therapeutics and Medisix Therapeutics; he is a co-founder of, stockholder of and consultant for Unum, Nkarta and Medisix. JCI Insight 2, e87032 (2017). Herberman, R. B., Nunn, M. E. & Lavrin, D. H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. Blood 131, 1053–1062 (2018). J. Exp. Immunity 50, 1381–1390.e5 (2019). This article reports how NK cells increase the number of dendritic cells in tumour sites by secreting the chemoattractans CCL5 and XCL1, and that NK cell/dendritic cell gene signatures correlate with outcome in several cancer types. J. Exp. A natural killer (NK) cell is a type of immune cell that patrols the body for unhealthy cells, including cancer cells. Trends Immunol. Immunol. Clin. J. Immunother. Bethesda, MD 20894, Copyright Sci. Blood 105, 721–727 (2005). J. Clin. Vivier, E. et al. J. Immunol. Guillerey, C., Huntington, N. D. & Smyth, M. J. Kudo, K. et al. Nat. Semin. Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. Blood Marrow Transplant. Morvan, M. G. & Lanier, L. L. NK cells and cancer: you can teach innate cells new tricks. In natural killer cells, anergy or hyporesponsiveness to activating signals might be caused by chronic stimulation during maturation through an activating receptor interacting with a self-ligand. 969, 203–220 (2013). 34, 573–582 (2013). Oncol. Med. 132, 515–525 (2013). Sci. Human NK cells proliferate and die in vivo more rapidly than T cells in healthy young and elderly adults. Biol. Front. Shimasaki, N. & Campana, D. Natural killer cell reprogramming with chimeric immune receptors. Transl Med. O’Sullivan, T. E., Sun, J. C. & Lanier, L. L. Natural killer cell memory. Selection and expansion of natural killer cells for NK cell-based immunotherapy. Front Immunol. Pathol. 379, 64–73 (2018). Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: clinical implications for cancer treatment. Accessibility Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML. Houchins, J. P., Lanier, L. L., Niemi, E. C., Phillips, J. H. & Ryan, J. C. Natural killer cell cytolytic activity is inhibited by NKG2-A and activated by NKG2-C. J. Immunol. Biol. IL-12-dependent inducible expression of the CD94/NKG2A inhibitory receptor regulates CD94/NKG2C+ NK cell function. 31, 413–441 (2013). Kolb HJ. Natural killer (NK) cells are a type of immune cell. Occurrence of nodular lymphocyte-predominant Hodgkin lymphoma in Hermansky-Pudlak type 2 syndrome is associated to natural killer and natural killer T cell defects. Corat, M. A. et al. & Strong, R. K. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc. Leukemia 18, 1835–1838 (2004). 26, 161–172 (2014). J. Clin. Cancer 16, 216–229 (1975). NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Brodin, P., Lakshmikanth, T., Johansson, S., Karre, K. & Hoglund, P. The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. 8, 533 (2017). 4, 101 (2013). Nat. Natural killer cell homing and persistence in the bone marrow after adoptive immunotherapy correlates with better leukemia control. Kasaian, M. T. et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. Thompson, T. W. et al. J. Immunol. J. Immunol. IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. 15, 4857–4866 (2009). Natural killer (NK) cells can swiftly kill multiple adjacent cells if these show surface markers associated with oncogenic transformation. Alici, E. et al. This article describes how NK cells, through secretion of FLT3L, control the abundance of intratumoural stimulatory dendritic cells and how their frequency directly correlates with survival in patients with melanoma receiving anti-PD-1 therapy. In recent years, successes in anti-tumor treatments with antibodies and cell-based immunotherapy has become landmark events in the history of tumor treatment (1, 2). IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Williams, S. M. et al. Parkhurst, M. R., Riley, J. P., Dudley, M. E. & Rosenberg, S. A. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Blood 90, 1109–1114 (1997). The use of NK cells in adoptive cancer immunotherapy is also expected 2021 Mar 22. doi: 10.1038/s41417-021-00320-w. Online ahead of print. Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. USA 105, 17481–17486 (2008). Mol. Med. Cytotherapy 18, 1422–1434 (2016). A procedure that removes white blood cells from blood,while returning the remainder blood components to circulation. Med. Amplified Natural Killer Cell Immunotherapy safely proliferates and activates large volumes of aggressive wild type* NK Cells in vitro, and infuses the cells back to the patient in up to 12 … Parihar, R. et al. Nat. Street, S. E. et al. 197, 967–976 (2003). CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Invest. Front. Immunity 27, 965–974 (2007). Miller, J. S. et al. Immunol. 5, 112–117 (1975). Cancer Res. Hsu, K. C. et al. Kamiya, T., Seow, S. V., Wong, D., Robinson, M. & Campana, D. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. Expression of the activating receptor, NKp46 (CD335), in human natural killer and T-cell neoplasia. Lapteva, N. et al. J. Immunol. Biol. Cancer Gene Ther. Ruscetti, M. et al. Proc. 2017 Aug 2;25(8):1769-1781. doi: 10.1016/j.ymthe.2017.06.012. Albertsson, P. A. et al. Med. 5, 112–117 (1975). Studies on the in vitro activation of Leu-11+ granular lymphocytes with a natural killer-sensitive tumor cell, K562. eCollection 2021. Gene regulatory programs conferring phenotypic identities to human NK cells. 182, 829–836 (2009). Orange, J. S. Formation and function of the lytic NK-cell immunological synapse. Sci. Successful transfer of umbilical cord blood CD34+ hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients. (2021), Advanced Therapeutics Nat. Immunity 28, 571–580 (2008). III. Cancer Immunotherapy Immunotherapy Strategies: Autologous Adoptive Cell Therapy. Expert Opin Biol Ther. Cancer Res. 9, ra19 (2016). Lee, D. A., Verneris, M. R. & Campana, D. Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. Immunol. Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell response. Tomchuck, S. L., Leung, W. H. & Dallas, M. H. Enhanced cytotoxic function of natural killer and CD3+CD56+ cells in cord blood after culture. Biol. To obtain Proc. This article describes how genetic engineering of activated NK cells expressing a NKG2D chimeric receptor markedly enhances their antitumour activity. Cichocki, F. et al. JCI Insight 3, 96219 (2018). 4, eaat8116 (2019). Cancer Res. Andre, P. et al. J. Lanier, L. L., Testi, R., Bindl, J. Blood Marrow Transplant. 2021;1316:71-85. doi: 10.1007/978-981-33-6785-2_5. Viant, C. et al. Blood 123, 809–821 (2014). Science 359, 1537–1542 (2018). This property, which is unique among immune cells, and their capacity to enhance antibody and T cell responses support a role for NK cells as anticancer agents. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK Cells. Mol Ther. Invest. Although tumours may develop several mechanisms to resist attacks from endogenous NK cells, ex vivo activation, expansion and genetic modification of NK cells can greatly increase their antitumour activity and equip them to overcome resistance. 2018 Dec 4;6(1):136. doi: 10.1186/s40425-018-0441-8. Med. J. Exp. Science 285, 730–732 (1999). Gasser, S., Orsulic, S., Brown, E. J. J. A TCR-based chimeric antigen receptor. Cell 177, 1701–1713 (2019). This article describes the first trial of recombinant human IL-15 administered after NK cell infusions in patients with AML, reporting NK cell expansion and toxic effects. J. Med. Leukemia 30, 456–463 (2016). Cancer Cell 32, 135–154 (2017). Blood 118, 6387–6391 (2011). A hypofunctional state. Front. 28, 897–913 (2017). These observations, in addition to the capacity of NK cells to magnify immune responses, suggest that NK cells are poised to become key components of multipronged therapeutic strategies for cancer. Nature 419, 734–738 (2002). 436, 1186–1190 (2005). Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. 127, 2777–2788 (2017). Blood Adv. Careers. Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at … Tam, Y. K., Martinson, J. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Cytokine activation induces human memory-like NK cells. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. J. Exp. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Prlic, M., Blazar, B. R., Farrar, M. A. Viel, S. et al. Immunol. Takeda, K. et al. Epub 2017 Nov 10. J. Immunol. Sci. Targeting NK-cell checkpoints for cancer immunotherapy. JCI Insight 1, e89829 (2016). Sci. Hsu, J. et al. Signal. Cancer 16, 216–229 (1975). J. Exp. 169, 4098–4102 (2002). Takeda, K. et al. Coudert, J. D. et al. NK cell heparanase controls tumor invasion and immune surveillance. 6, 228ra237 (2014). 18, 671–688 (2018). Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. 2003 Apr;3(2):237-50. doi: 10.1517/14712598.3.2.237. 186, 4590–4598 (2011). With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating haematological malignancies, there is a rapid growing interest in developing CAR-engineered NK (CAR-NK) cells for cancer therapy. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Blood Marrow Transplant. & Campana, D. NK cells for cancer immunotherapy. Unable to load your collection due to an error, Unable to load your delegates due to an error. Finally, there is emerging evidence of increased NK cell-mediated tumour cell killing in the context of molecularly targeted therapies. Walseng, E. et al. Cifaldi L, Locatelli F, Marasco E, Moretta L, Pistoia V. Trends Mol Med. Res. Oncoimmunology 5, e1219007 (2016). Targeting natural killer cells in cancer immunotherapy. 21, 632–639 (2015). Shah, N. N. et al. J. Exp. Google Scholar. 20, 463–473 (2014). 651, 61–77 (2010). Although NK cells can discriminate between “self” and “non-self,” recognize abnormal cells, and eliminate transformed cells and malignancies in real time, tumors develop several strategies to escape from NK cell attack. Romagne, F. et al. 35, 285–311 (2017). A condition resulting from the systemic attack of allogenic T cells on the tissues of an immunosuppressed recipient, which, in its most severe grade, is fatal. Immunity 43, 634–645 (2015). Farag SS, Fehniger TA, Becknell B, Blaser BW, Caligiuri MA. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. 32, 177–186 (2003). As innate immune cells, natural killer (NK) cells are unique and play pivotal functions in cancer immune surveillance. Exp. Engineered cells as glioblastoma therapeutics. Trends Immunol. B., Barak, V. & Nagler, A. Ex vivo expansion of CD56+cytotoxic cells from human umbilical cord blood. Raulet, D. H. & Vance, R. E. Self-tolerance of natural killer cells. 12, 269–281 (2012). Nat. National Library of Medicine Nature 408, 57–63 (2000). Nat Rev Drug Discov 19, 200–218 (2020). & Ravetch, J. V. Signaling by antibodies: recent progress. A growing number of scientific reports and clinical studies have shown promising anti-tumor effects when using NK cell-based immunotherapy. Int. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes. Rautela, J. et al. Williams, R. L. et al. Crinier, A. et al. Davis, Z. 32, 364–372 (2011). This is one of the first studies to show that a second-generation anti-CD19 CAR can be expressed in NK cells after ex vivo expansion, overcome inhibitory signals and trigger specific killing of B cell ALL. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Geller, M. A. et al. ISSN 1474-1784 (online). PubMed Central  I. Semeraro, M., Rusakiewicz, S., Zitvogel, L. & Kroemer, G. Natural killer cell mediated immunosurveillance of pediatric neuroblastoma. 74, 93–103 (2014). Natural Killer Cells in Immunotherapy Complimentary cancer treatment centers are devoted to helping the patient understand the complex nature of treatment. J. Immunother. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. 3, 897–907 (2019). TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Kweon, S. et al. Reeves, R. K. et al. 2, 274–283 (2013). Distribution of reactivity and specificity. Hammer, Q. et al. eLife 6, e30881 (2017). Blood. Kloss, S. et al. Kaiser, B. K., Pizarro, J. C., Kerns, J. 24, 618–622 (2018). Immunity 43, 394–407 (2015). Harada, H., Watanabe, S., Saijo, K., Ishiwata, I. 20, 1129–1137 (2019). Borrego, F. et al. PubMed  79, 4149–4159 (2019). Chang, Y. H. et al. Signal. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. Rev. 207, 2065–2072 (2010). A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Immunol. In silico modeling identifies CD45 as a regulator of IL-2 synergy in the NKG2D-mediated activation of immature human NK cells. 73, 1777–1786 (2013). Sci. Gooden, M. et al. In addition to technical barriers, the biggest challenge in NK cell immunotherapy for cancers is the lack of in‐depth understanding of the underlying mechanisms of NK cell dysfunction, not only in tumours, but also during ex vivo expansion before adoptive transfer. Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma. Bone Marrow Transplant. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Natural killer (NK) cells have the potential to solve these inadequacies of T cells and are emerging as a safe and effective mode of treatment for several hard-to-treat cancers. NK and T cells share many of the costimulatory and inhibitory receptors that are currently under evaluation in the clinic for cancer immunotherapy. Young, A. et al. Gab3 is required for IL-2- and IL-15-induced NK cell expansion and limits trophoblast invasion during pregnancy. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. They can kill cancer and virally infected cells. Giebel, S. et al. J. Immunol. 38, 197–210 (2015). Mukherjee, S. et al. Immunity 31, 99–109 (2009). Modak, S. et al. & Phillips, J. H. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. Yu, J., Freud, A. G. & Caligiuri, M. A. Online ahead of print. Campana, D. & Pui, C. H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. J. Immunol. Blood 122, 1341–1349 (2013). Med. & Melero, I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Bryceson, Y. T., March, M. E., Ljunggren, H. G. & Long, E. O. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. CAS  NK cell represents a specialized immune effector cell population equipped with fast-acting and potent anti-tumor capacity. Clin. J. Med. 23, 4107–4118 (2017). Get time limited or full article access on ReadCube. Ettinghausen, S. E. et al. Staaf, E. et al. Educated natural killer cells show dynamic movement of the activating receptor NKp46 and confinement of the inhibitory receptor Ly49A. Cell 172, 1022–1037 (2018). 10, 879 (2019). Rev. Distribution of reactivity and specificity. Nat. PubMed  35, 765–772 (2017). Front Oncol. Blood 111, 3155–3162 (2008). Gao, Y. et al. Cytotherapy 11, 341–355 (2009). Cytotherapy 18, 653–663 (2016). J. Clin. Nature. Potential targets of natural killer (NK) cell‐based cancer immunotherapy. Stem Cell Transl. Lipid Metabolism in Tumor-Associated Natural Killer Cells. Blood 130, 1857–1868 (2017). 24, 5552–5561 (2018).